Combination therapy for alzheimers disease

Drugs and Aging

Volumn 28, Issue 7, 2011, Pages 539-546

  Patel, Laxeshkumar ^a   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimers disease; Cholinesterase inhibitors; Donepezil; Galantamine; Memantine; NMDA receptor antagonists; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; CYCLOSERINE; DONEPEZIL; GALANTAMINE; MEMANTINE; MILACEMIDE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; BEHAVIOR; COGNITION; COMBINATION CHEMOTHERAPY; CONFUSION; DAILY LIFE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; HUMAN; MONOTHERAPY; MORNING DOSAGE; MUSCLE HYPERTONIA; NAUSEA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; METHODOLOGY; TIME;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; MEMANTINE; TIME FACTORS;

EID: 79959987552     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11591860-000000000-00000     Document Type: Review

References (40)

1. Cummings JL, Cole G. Alzheimer disease. JAMA 2002; 287: 2335-8 (Pubitemid 34493187)
2. Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and meta-regression analysis.ArchGen Psychiatry 2006; 63: 530-8
3. Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimers disease. J Neuropsychiatry Clin Neurosci 2003; 15:346-53 (Pubitemid 36999378)
4. Burns A, Iliffe S. Alzheimers disease. BMJ 2009; 338: b158
5. Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimers disease. Science 2006; 314: 781-4 (Pubitemid 44706637)
6. Folwell J, Cowan CM, Ubhi KK, et al. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimers disease. Exp Neurol 2010 Jun; 223 (2): 401-9
7. Winblad B. Socio-economic perspectives of dementia and cost-effectiveness of treatment. 7th International Geneva/ Springfield Symposium on Advances in Alzheimer Therapy; 2002 Apr 3-6; Geneva
8. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-22
9. Rösler M, Anand R, Cicin-Sain A, et al Efficacy and safety of rivastigmine in patients with Alzheimers disease: international randomised controlled trial. BMJ 1999 318 633-8
10. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimers disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445-9
11. Winblad B, Wimo A, Engedal K, et al. 3-Year study of donepezil therapy in Alzheimers disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21: 353-63 (Pubitemid 43735680)
12. Black S, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69: 459-69 (Pubitemid 47450281)
13. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimers disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-65
14. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimers disease. Neurology 2001; 57: 613-20 (Pubitemid 32782987)
15. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebocontrolled trial. Arch Neurol 2004; 61: 1852-6 (Pubitemid 39612945)
16. Ritchie CW, Ames D, Clayton T, et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004 Jul-Aug; 12 (4): 358-69 (Pubitemid 38878856)
17. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimers disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3 (2): 211-25 (Pubitemid 352037861)
18. Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135-46 (Pubitemid 29110331)
19. Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimers disease. N Engl J Med 2003; 348: 1333-41
20. Dysken MW, Mendels J, LeWitt P, et al. Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 1992; 40: 503-6
21. Laake K, Oeksengaard AR. D-cycloserine for Alzheimers disease. Cochrane Database Syst Rev 2002; 2: CD003153
22. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimers disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291 (3): 317-24 (Pubitemid 38101604)
23. van Dyck CH, Schmitt FA, Olin JT. Memantine MEMMD- 02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry 2006; 14 (5): 428-37
24. Rountree SD, ChanW, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009; 1: 7
25. Atri A, Shaughnessy LW, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008 Jul-Sep; 22 (3): 209-21
26. Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimers disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008 Feb; 5 (1): 83-9 (Pubitemid 351536358)
27. Peskind ER, Potkin SG, PomaraN, et al.Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized controlled trial. Am J Geriatr Psychiatry 2006; 14: 704-15 (Pubitemid 44196270)
28. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimers disease: results of a randomized, doubleblind, placebo-controlled 6-month study. J Alzheimers Dis 2007; 11: 471-9 (Pubitemid 47094022)
29. Hartmann S, Möbius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003; 18: 81-5 (Pubitemid 36343976)
30. Yao C, Raoufinia A, Gold M, et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol 2005; 45: 519-28 (Pubitemid 40562942)
31. Shua-Haim JR, Smith J, Pass M, et al. Safety, tolerability, and caregivers impressions of combination therapy with galantamine and memantine for the treatment of Alzheimers disease [abstract P1-392]. Poster presented at the American Psychiatric Association 2004 Annual Meeting; 2004 Jul 17-22; Philadelphia (PA
32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
33. Ramaswamy K. Safety of galantamine-memantine combination treatment for mild to moderate Alzheimers disease. Poster presented at the 57th Institute on Psychiatric Services; 2005 Oct 5-9; San Diego (CA
34. Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimers disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2010 Apr; 25 (4): 419-26
35. FarlowMR, AlvaG,Meng X, et al. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis.CurrMed ResOpin 2010 Feb; 26 (2): 263-9
36. Lopez OL, Becker JT,Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009 Jun; 80 (6): 600-7
37. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimers disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18 Suppl. 1: S23-32 (Pubitemid 37150475)
38. Reisberg B, Doody R, Stöffler A, et al.A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006 Jan; 63 (1): 49-54 (Pubitemid 43063861)
39. Mohs RC, Kawas C, Carrillo MC. Optimal design of clinical trials for drugs designed to slow the course of Alzheimers disease. Alzheimer Dement 2006; 2: 131-9 (Pubitemid 43843103)
40. Martinez-Coria H, Green KN, BillingsLM, et al. Memantine improves cognition and reduces Alzheimers-like neuropathology in transgenic mice. Am J Pathol 2010 Feb; 176 (2): 870-80